News | November 11, 2022
Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The company is making its entry into the Hyderabad market through its unique asset-light business model
The Group will continue to make proactive investments of its management resources in the life science business
The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Subscribe To Our Newsletter & Stay Updated
